A proteomic atlas of kidney amyloidosis provides insights into disease pathogenesis
Charalampos Charalampous(Mayo Clinic), Taxiarchis Kourelis(Mayo Clinic in Arizona), Morie A. Gertz(Medical University of South Carolina), Nelson Leung(WinnMed), Ellen D. McPhail(Mayo Clinic), Surendra Dasari(Mayo Clinic in Arizona), Eli Muchtar(WinnMed), Jason D. Theis(Mayo Clinic), Angela Dispenzieri(Mayo Clinic), Julie A. Vrana(Mayo Clinic), Marina Ramı́rez-Alvarado(WinnMed)
Cited by 14
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k